Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EBITDA (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of EBITDA data on record, last reported at -$97.0 million in Q4 2025.

  • For Q4 2025, EBITDA fell 51.74% year-over-year to -$97.0 million; the TTM value through Dec 2025 reached -$326.2 million, down 62.96%, while the annual FY2025 figure was -$326.2 million, 62.96% down from the prior year.
  • EBITDA reached -$97.0 million in Q4 2025 per PRAX's latest filing, down from -$78.4 million in the prior quarter.
  • Across five years, EBITDA topped out at -$25.5 million in Q3 2023 and bottomed at -$97.0 million in Q4 2025.
  • Average EBITDA over 4 years is -$54.2 million, with a median of -$50.6 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 44.67% in 2023, then plummeted 130.01% in 2024.
  • A 4-year view of EBITDA shows it stood at -$41.5 million in 2022, then soared by 32.92% to -$27.8 million in 2023, then tumbled by 130.01% to -$64.0 million in 2024, then plummeted by 51.74% to -$97.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$97.0 million in Q4 2025, -$78.4 million in Q3 2025, and -$76.1 million in Q2 2025.